Clinical Trial

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
Protocol Amendment History 4 changes
critical Enrollment reopened 2026-08-11
notable Enrollment reduced: 57 -> 42 participants 2026-05-28
notable Primary completion moved earlier: 2029-01-10 -> 2027-08-03 2026-05-28
minor Completion moved earlier: 2029-01-10 -> 2027-08-03 2026-05-28
Trial Details
NCT Number NCT06880549
Lead Sponsor ModernaTX, Inc.
Conditions Advanced Solid Tumors
Enrollment 42 participants
Start Date 2025-03-25
Primary Completion 2027-08-03 (estimated)
Study Completion 2027-08-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-10